The panel of experts shift their discussion to the adult acute lymphoblastic leukemia setting, considering the potential to improve patient outcomes with chimeric antigen receptor (CAR) T-cell therapy.

Jennifer Mack, MD, MPH, Medical Director of Inpatient Oncology at Dana-Farber Boston Children's Cancer and Blood Disorders Center, discusses chemotherapy versus radiation in the treatment of acute lymphoblastic leukemia (ALL).

This is the third video in the series of Hematology.Acute leukemias are the neoplastic proliferation of the blasts within the bone marrow and the leukemias which arise from the lymphoblasts are called as the Acute lymphoblastic leukemia.
These are of two types, B ALL and T AlL

Mark R. Litzow, MD; Ryan D. Cassaday, MD; Aaron C. Logan, MD, PhD; Bijal D. Shah, MD; and Anthony S. Stein, MD, reflect on the complexities of the risk stratification process in acute lymphoblastic leukemia, incorporating patient age, molecular subtype, and minimal residual disease status.

In this segment, Raoul Tibes, MD, PhD, discusses risk stratification based on minimal residual disease monitoring in patients with acute lymphoblastic leukemia achieve remission.

The discussants, Bijal D. Shah, MD, and Raoul Tibes, MD, PhD, elaborate on the administration and safety of bi-specific T-cell engager, blinatumomab, in the treatment of acute lymphoblastic leukemia.

Jennifer Mack, MD, MPH, Medical Director of Inpatient Oncology at Dana-Farber Cancer Institute/Children's Hospital Boston, explains why some kids more likely to develop acute lymphoblastic leukemia (ALL) then others.